AlphaFold predicted structure
SMPD4 · Q9NXE4

Mean pLDDT
71.3/ 100
Confident
866 residues
Confidence breakdown
- Very high(≥ 90)28%
- Confident(70–90)33%
- Low(50–70)14%
- Very low(< 50)25%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
sphingomyelin phosphodiesterase 4
Annotations refreshed 10 hours ago.
Diagnostic Grade (Green)
Arthrogryposis
BIALLELIC, autosomal or pseudoautosomalCerebellar hypoplasia
BIALLELIC, autosomal or pseudoautosomalDDG2P
BIALLELIC, autosomal or pseudoautosomalFetal anomalies
BIALLELIC, autosomal or pseudoautosomalIntellectual disability
BIALLELIC, autosomal or pseudoautosomalMonogenic diabetes
BIALLELIC, autosomal or pseudoautosomalAtaxia and cerebellar anomalies - narrow panel
BIALLELIC, autosomal or pseudoautosomalChildhood onset dystonia, chorea or related movement disorder
+1 more panels — install the extension to see the full list inline on any page.
neurodevelopmental disorder with microcephaly, arthrogryposis, and structural brain anomalies
neurodegenerative disease
hereditary disease
diabetes mellitus
type 1 diabetes mellitus
Abnormal cerebral morphology
microcephaly
hepatocellular carcinoma
urinary bladder cancer
urinary bladder carcinoma
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Sphingomyelin phosphodiesterase 4
Catalyzes the hydrolysis of membrane sphingomyelin to form phosphorylcholine and ceramide (PubMed:16517606, PubMed:25180167). It has a relevant role in the homeostasis of membrane sphingolipids, thereby influencing membrane integrity, and endoplasmic reticulum organization and function (PubMed:31495489). May sensitize cells to DNA damage-induced apoptosis (PubMed:18505924). In skeletal muscle, mediates TNF-stimulated oxidant production (By similarity)
SMPD4 · Q9NXE4

Mean pLDDT
71.3/ 100
Confident
866 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0